Lilly announces transitions in executive leadership

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide.
Lilly noted it has experienced significant growth over the past several years, particularly in the US and cardiometabolic health businesses, not least with its obesity and diabetes drugs – tirzepatide trade-named Mounjaro and Zepbound. The company anticipates continued growth in these areas, along with further pipeline advancement. To help drive this next wave of growth, Lilly is increasing its leadership focus on the US business and global therapeutic areas.

Ilya Yuffa, executive vice president and president, Lilly International, will become executive vice president and president, Lilly USA and Global Customer Capabilities. In this capacity, Mr Yuffa will lead the US business, including sales, marketing, and commercial capabilities for all marketed products, and will be responsible for the commercialization of upcoming product launches in the USA.

Patrik Jonsson, executive vice president and president, Lilly Cardiometabolic Health, and president, Lilly USA, will become executive vice president and president, Lilly International and will lead all markets outside the USA. Jonsson's leadership of Lilly's cardiometabolic and US businesses has driven significant growth and increased market leadership.